+ Follow FIRST PIVOTAL PHASE Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 152317
[Title] => Giant German pharma set to launch newest anti-"ED" preparation
[Summary] => Leverkusen, Germany - First Pivotal Phase III data for vardenafil, Bayer’s new, highly selective phosphodiesterase-5 inhibitor for erectile dysfunction (ED), show statistically significant improvements in erectile function and consistency in response among up to 85 percent of the broad population of men treated. The data was presented last December at the Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Charleston, South Carolina/USA.
[DatePublished] => 2002-03-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
FIRST PIVOTAL PHASE
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 152317
[Title] => Giant German pharma set to launch newest anti-"ED" preparation
[Summary] => Leverkusen, Germany - First Pivotal Phase III data for vardenafil, Bayer’s new, highly selective phosphodiesterase-5 inhibitor for erectile dysfunction (ED), show statistically significant improvements in erectile function and consistency in response among up to 85 percent of the broad population of men treated. The data was presented last December at the Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Charleston, South Carolina/USA.
[DatePublished] => 2002-03-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
)
)
abtest
